<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127791">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961375</url>
  </required_header>
  <id_info>
    <org_study_id>16199</org_study_id>
    <secondary_id>MA1210IN</secondary_id>
    <nct_id>NCT01961375</nct_id>
  </id_info>
  <brief_title>MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study</brief_title>
  <acronym>MIDAS</acronym>
  <official_title>MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as non interventional to observe the continuation rate and the patient
      satisfaction in women who have a  LNG-IUS (Levonorgestrel releasing Intrauterine system)
      inserted for contraception over the period of 12 months under real life condition in
      India.The study will begin after the study approval by ethics committee.All Indian women
      aged between 18-49 years who are initiating LNG IUS therapy for contraception  will be
      included in study after taking the informed consent.Patients will be observed for upto 12
      months.The study involves general examination of patients, collection of data like medical
      history, previous contraceptive use,concomitant medication etc.The study is planned to
      enroll 600 subjects from multiple study centers spread across India. The study data will be
      analyzed with appropriate statistical methods.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage continuation rate of LNG IUS at end of observation period</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative discontinuation rate for pregnancy</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative discontinuation rate for other medical reasons</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative discontinuation rate for non-medical reasons</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage of women with amenorrhea</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent of women with spotting, inter-menstrual bleeding</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of contraceptive usage patterns</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>contraceptive usage patterns included:birth-spacing, long term contraception, postpartum contraception, post-abortion contraception, switch from other method, contraception for other medical reasons like heart disease, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of drug-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>BAY 86-5028; Levonorgestrel- Intra Uterine System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)</intervention_name>
    <description>Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study subjects will be enrolled from multiple sites like women's hospitals, tertiary
        care institutes, Family planning clinics and gynaecological consulting centres
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged between 18-49 years who are initiating LNG IUS therapy for
             contraception.

          -  Subject willing to provide informed consent and comply with study procedure

        Exclusion Criteria:

          -  Exclusion criteria must be read in conjunction with the local product information
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
